Information Provided By:
Fly News Breaks for October 23, 2015
SPPI
Oct 23, 2015 | 10:24 EDT
RBC Capital said Sprecturm weakness related to the unexpected complete response letter for Evomela seems like and overreaction. Analyst Adnan Butt said the complete response letter does not appear to be related to bioequivalence, efficacy or safety. Butt said this is a small product from a top-line growth perspective and said the pipeline matters much more where 66% of is $13 price target comes from and his Outperform rating.
News For SPPI From the Last 2 Days
There are no results for your query SPPI